Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer|Breast Carcinoma
Sponsor: Pfizer